MCRI to build on CyGenics' stem cell scaffold

By Melissa Trudinger
Friday, 13 August, 2004

Stem cell company CyGenics (ASX: CYN) will collaborate with the Murdoch Children's Research Institute to perform clinical trials demonstrating that stem cells expanded from umbilical cord blood using CyGenics subsidiary Cytomatrix's proprietary cell growth scaffold retain full functionality and effectiveness.

Cytomatrix will transfer the technology, which has been shown to work for the expansion of human bone marrow stem cells, cord blood stem cells and peripheral blood stem cells, to researchers working at the MCRI.

A grant of AUD$50,000 has been awarded to the company through the Federal Government's International Science Linkages Program to support the trials.

Related News

Anti-inflammatory agent could decrease septic shock mortality

Researchers have discovered a naturally occurring blood protein — a type of...

Less penicillin needed to treat Strep A infection than we thought

It's never been known exactly how much penicillin prevents sore throats — the most...

Stress disrupts emotion control in mental illness

Acute stress may impair key brain functions involved in managing emotions — particularly in...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd